23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          High-sensitivity troponin-I (hs-TnI) measurement improves risk assessment for cardiovascular events in many clinical settings, but the added value in atrial fibrillation patients has not been described.

          Related collections

          Author and article information

          Journal
          Circulation
          Circulation
          Ovid Technologies (Wolters Kluwer Health)
          1524-4539
          0009-7322
          Feb 11 2014
          : 129
          : 6
          Affiliations
          [1 ] Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (Z.H., A.S., U.A., L.W.); Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden (Z.H., U.A., L.W.); Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden (A.S.); Duke University, Medical Center, Durham, NC (C.B.G., J.H.A., R.D.L.); Department of Cardiology, Oslo University Hospital and Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, Oslo, Norway (D.A.); Mayo Clinic College of Medicine, Rochester, MN (B.J.G.); Bristol-Myers Squibb, Princeton, NJ (P.M.); Division of Emergency Care, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (V.-P.H.); University of Adelaide, Adelaide, Australia (J.H.); Medical Department, Hospital Unit West, Herning/Holstbro, Denmark (S.H.); Boston University Medical Center, Boston, MA (E.M.H.); and BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M.).
          Article
          CIRCULATIONAHA.113.006286
          10.1161/CIRCULATIONAHA.113.006286
          24226808
          4b1a494d-e071-43e4-919d-8b36e750c2d2
          History

          atrial fibrillation,biological markers,cardiovascular diseases,risk assessment,troponin

          Comments

          Comment on this article